ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.

Study Overview

• Status: Terminated
• Conditions: Persistent Corneal Epithelial Defect
• Intervention / Treatment: Biological: ST266; Biological: Open-label ST266; Other: 0.67% Sodium Chloride Ophthalmic Solution

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Dothan, Alabama, United States, 36301
      • Trinity Research Group
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • University of Arkansas for Medical Sciences
  • California
    • Huntington Beach, California, United States, 92647
      • Atlantis Eye Care
    • Los Angeles, California, United States, 90095
      • UCLA Stein Eye Institute
    • Palo Alto, California, United States, 94303
      • Stanford
    • Pasadena, California, United States, 91105
      • UCLA Doheny Eye Center
    • Pasadena, California, United States, 91107
      • California Eye Specialists Medical Group
  • Florida
    • Jacksonville, Florida, United States, 32259
      • Bowden Eye & Associates
    • Largo, Florida, United States, 33733
      • Shettle Eye Research
    • Miami, Florida, United States, 33143
      • MedEye Associates
    • Miami, Florida, United States, 33125
      • Millennium Clinical Research, INC
  • Kentucky
    • Edgewood, Kentucky, United States, 41017
      • Cincinnati Eye Institute
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland Eye Associates
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Tufts Medical Center
    • Boston, Massachusetts, United States, 02114
      • Massachusetts Eye and Ear
  • Missouri
    • Springfield, Missouri, United States, 65804
      • Mercy Clinic Eye Specialists- Ophthalmology
  • Nebraska
    • Omaha, Nebraska, United States, 68105
      • UNMC Truhlsen Eye Institute
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27517
      • UNC Kittner Eye Center
  • Ohio
    • Cincinnati, Ohio, United States, 45242
      • Cincinnati Eye Institute
    • Columbus, Ohio, United States, 43212
      • OSU Wexner Medical Center
  • Pennsylvania
    • Bala-Cynwyd, Pennsylvania, United States, 19004
      • Ophthalmic Partners, PC
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt Eye Institute
  • Texas
    • Houston, Texas, United States, 77030
      • Baylor College of Medicine
    • Houston, Texas, United States, 77025
      • Houston Eye Associates
    • Houston, Texas, United States, 77030
      • Blanton Eye Institute/Houston Methodist Eye Associates
    • Hurst, Texas, United States, 76054
      • Texas Eye Research Center
    • San Antonio, Texas, United States, 78229
      • R and R Eye Research, LLC
  • Virginia
    • Lynchburg, Virginia, United States, 34502
      • Piedmont Eye Center
  • West Virginia
    • Morgantown, West Virginia, United States, 26505
      • WVU Eye Institute
  • Wisconsin
    • Kenosha, Wisconsin, United States, 53142
      • The Eye Centers of Racine and Kenosha
    • Madison, Wisconsin, United States, 53705
      • University of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and non-pregnant/non-breastfeeding female subjects aged 18 years and older.
2. Subjects with a PED present for at least seven (7) days at the time of Screening.
3. The defect must be at least 1.0 mm (longest linear measurement) at Screening and Baseline (Day 1) and must be measurable by slit lamp.
4. In the Investigator's opinion, the defect is persistent i.e., the defect has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.
5. The original defect to the cornea must be the result of an injury, infection, disease, or surgery to the eye.

Exclusion Criteria:

1. Diabetic cohort only: enrollment will be limited to include up to 50% of subjects with diabetes, as indicated by HbA1c level >6.5%. Subjects with a HbA1c level >6.5% after closure of the diabetic cohort will be excluded.
2. Subjects currently being treated with cenegermin or other rhNGF in the study eye.
3. Subjects currently using topical antibiotic eye drops in the study eye. Subjects on current antibiotic therapy must be willing to switch to study-provided moxifloxacin.
4. Subjects currently taking topical steroids or corticosteroid-containing eye drops or ointment in the study eye. Subjects currently taking systemic corticosteroids with a dose of >10mg/day prednisone or equivalent.
5. Subjects currently using topical antihistamine eye drops or vasoconstrictors in the study eye.
6. Subjects currently using topical or local immunosuppressive agents (e.g., optic cyclosporine or lifitegrast) in the study eye.
7. Subjects who require treatment with autologous serum eyedrops or amnion products in the study eye.
8. Subjects who need to use contact lenses for refractive correction during the study.
9. Subjects who require treatment with bandage contact lens or punctal plugs in the study eye that cannot be removed.
10. Subjects currently taking antiviral medications for an active infection in the study eye. Subjects taking antiviral medications for prophylaxis may be enrolled in the study at the Investigator's discretion, provided that the subject remain on a stable dosing regimen throughout the duration of the study.
11. History of ocular surgery (including laser or refractive surgery) in the study eye within 1 month prior to study screening or, in the opinion of the Investigator, there are persistent post-surgical complications that would impact the study data.
12. Subjects with an uncontrolled lid or ocular infection in the study eye.
13. History of alkali burns of the cornea.
14. The circumference affected by limbal blood vessel ischemia is greater than 75 percent of the limbal circulation.
15. Subjects with severe lid abnormalities contributory to the persistence of the PED such as inability to close the lids.
16. Subjects who have a history of AIDS or HIV.
17. Subjects who have participated in a clinical trial (including a previous study involving ST266) within 30 days prior to Day 1.
18. Subjects who have more than one distinct PED in the study eye prior to screening visits. Subjects who develop PEDs after the screening visit will remain in the study; however, only the original study PED will be assessed.
19. For subjects with bilateral PEDs, only the eye with the larger PED should be entered into the study. The non-study eye will receive standard of care treatment and be observed throughout the trial.
20. Subjects with bullous keratopathy in the study eye.
21. Subjects with corneal perforation or impending corneal perforation in the study eye.
22. Subjects with uncontrolled glaucoma.
23. Female subjects who are pregnant or breastfeeding. Female subjects who are neither postmenopausal for at least 1 year nor surgically sterile require a negative urine pregnancy test. All subjects must use an acceptable form of birth control during the study such as abstinence, barrier method, or hormonal contraceptive.
24. Epithelial defect was classified as a progressive corneal melt caused by an immunological process such as rheumatoid melt or Mooren's ulceration.
25. Subjects with recurrent corneal erosion or corneal basement membrane dystrophy.
26. Known hypersensitivity to study provided lubricating drops, antibiotic drops, and/or procedural medications such as fluorescein dye.
27. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ST266.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ST266; Topical ocular application: one drop in the study eye four times a day for 8 weeks	Biological: ST266; Topical ocular application: one drop four times a day for eight weeks; Biological: Open-label ST266; Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
Placebo Comparator: Placebo; Topical ocular application: one drop in the study eye four times a day for 8 weeks	Biological: Open-label ST266; Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks; Other: 0.67% Sodium Chloride Ophthalmic Solution; Topical ocular application: one drop four times a day for eight weeks; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Success	Proportion of subjects with clinical success between ST266 and placebo arms, defined as complete re-epithelialization of the corneal epithelial defect by week 8 of treatment.	8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of ST266	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in subjects treated with ST266 versus placebo	7 months
Time to re-epithelialization	Time (in days) to first complete re-epithelization of PED in subjects treated with ST266 versus placebo.	8 weeks
Maintenance of re-epithelialization during treatment	Time (in days) of re-epithelialization maintenance during treatment.	8 weeks
Maintenance of re-epithelialization post-treatment	Maintenance of corneal re-epithelization at 2 weeks and up to 12 weeks after the end of treatment in subjects treated with ST266 versus placebo.	12 weeks
Change in BCVA from Baseline	Mean change in Best Corrected Visual Acuity (BCVA) from Baseline over time and maintenance up to 12 weeks after the end of treatment in subjects treated with ST266 versus placebo.	7 months
Incidence of Rescue Therapy	Incidence of need for rescue within 8 weeks in subjects treated with ST266 versus placebo.	8 weeks
Clinical Success in Open-Label Extension	Proportion of subjects with complete re-epithelization of the corneal epithelial defect after 8 weeks of open label treatment based on the Independent Reading Center (IRC) image assessment.	8 weeks
Use of Lubricating Drops	Mean usage of preservative-free lubricating drops used for comfort in subjects treated with ST266 versus placebo.	8 weeks
VAS Score	Mean change in Visual Analog Scale (VAS) score from Baseline over time in subjects treated with ST266 versus placebo.	8 weeks
Size of Defect	Size of epithelial defect	7 months

Collaborators and Investigators

• Sponsor: Noveome Biotherapeutics, formerly Stemnion
• Collaborators: IQVIA Biotech

Study record dates

Study Major Dates

• Study Start (Actual): April 27, 2022
• Primary Completion (Actual): September 7, 2022
• Study Completion (Actual): September 7, 2022

Study Registration Dates

• First Submitted: September 23, 2021
• First Submitted That Met QC Criteria: September 23, 2021
• First Posted (Actual): October 4, 2021

Study Record Updates

• Last Update Posted (Actual): October 25, 2022
• Last Update Submitted That Met QC Criteria: October 24, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pharmaceutical Solutions; Ophthalmic Solutions
• Other Study ID Numbers: ST266-PED-202

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No